213 related articles for article (PubMed ID: 34404716)
1. Serological surveys to estimate cumulative incidence of SARS-CoV-2 infection in adults (Sero-MAss study), Massachusetts, July-August 2020: a mail-based cross-sectional study.
Snyder T; Ravenhurst J; Cramer EY; Reich NG; Balzer L; Alfandari D; Lover AA
BMJ Open; 2021 Aug; 11(8):e051157. PubMed ID: 34404716
[TBL] [Abstract][Full Text] [Related]
2. Serological surveys to estimate cumulative incidence of SARS-CoV-2 infection in adults (Sero-MAss study), Massachusetts, July-August 2020: a mail-based cross-sectional study.
Snyder T; Ravenhurst J; Cramer EY; Reich NG; Balzer LB; Alfandari D; Lover AA
medRxiv; 2021 May; ():. PubMed ID: 33758898
[TBL] [Abstract][Full Text] [Related]
3. Seroprevalence of SARS-CoV-2-specific anti-spike IgM, IgG, and anti-nucleocapsid IgG antibodies during the second wave of the pandemic: A population-based cross-sectional survey across Kashmir, India.
Lone KS; Khan SMS; Qurieshi MA; Majid S; Pandit MI; Haq I; Ahmad J; Bhat AA; Bashir K; Bilquees S; Fazili AB; Hassan M; Jan Y; Kaul RR; Khan ZA; Mushtaq B; Nazir F; Qureshi UA; Raja MW; Rasool M; Asma A; Bhat AA; Chowdri IN; Ismail S; Jeelani A; Kawoosa MF; Khan MA; Khan MS; Kousar R; Lone AA; Nabi S; Qazi TB; Rather RH; Sabah I; Sumji IA
Front Public Health; 2022; 10():967447. PubMed ID: 36276377
[TBL] [Abstract][Full Text] [Related]
4. Seropositivity of SARS-CoV-2 in an unvaccinated cohort in British Columbia, Canada: a cross-sectional survey with dried blood spot samples.
Racey CS; Booth A; Albert A; Smith LW; Krajden M; Murray MCM; Côté HCF; Gottschlich A; Goldfarb DM; Sadarangani M; Galea LAM; Kaida A; Brotto LA; Ogilvie GS
BMJ Open; 2022 Aug; 12(8):e062567. PubMed ID: 36038173
[TBL] [Abstract][Full Text] [Related]
5. Estimated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Based on Blood Donations, July 2020-May 2021.
Jones JM; Stone M; Sulaeman H; Fink RV; Dave H; Levy ME; Di Germanio C; Green V; Notari E; Saa P; Biggerstaff BJ; Strauss D; Kessler D; Vassallo R; Reik R; Rossmann S; Destree M; Nguyen KA; Sayers M; Lough C; Bougie DW; Ritter M; Latoni G; Weales B; Sime S; Gorlin J; Brown NE; Gould CV; Berney K; Benoit TJ; Miller MJ; Freeman D; Kartik D; Fry AM; Azziz-Baumgartner E; Hall AJ; MacNeil A; Gundlapalli AV; Basavaraju SV; Gerber SI; Patton ME; Custer B; Williamson P; Simmons G; Thornburg NJ; Kleinman S; Stramer SL; Opsomer J; Busch MP
JAMA; 2021 Oct; 326(14):1400-1409. PubMed ID: 34473201
[TBL] [Abstract][Full Text] [Related]
6. Estimated SARS-CoV-2 Seroprevalence in US Patients Receiving Dialysis 1 Year After the Beginning of the COVID-19 Pandemic.
Anand S; Montez-Rath M; Han J; Cadden L; Hunsader P; Kerschmann R; Beyer P; Boyd SD; Garcia P; Dittrich M; Block GA; Parsonnet J; Chertow GM
JAMA Netw Open; 2021 Jul; 4(7):e2116572. PubMed ID: 34251441
[TBL] [Abstract][Full Text] [Related]
7. [Seroprevalence of anti-SARS-CoV-2 IgG/IgM antibodies in Borgosesia (Piedmont Region, Northern Italy) population: a surveillance strategy in post-lockdown period?].
Alessi D; Borré S; Barale A; Isabella A; Milano F; Rossi MA; Silano V; Piu N; Cena T; Faggiano F;
Epidemiol Prev; 2020; 44(5-6 Suppl 2):200-206. PubMed ID: 33412811
[TBL] [Abstract][Full Text] [Related]
8. Assessment of initial SARS-CoV-2 seroprevalence in the most affected districts in the municipality of São Paulo, Brazil.
Tess BH; Granato CFH; Alves MCGP; Pintão MCT; Nunes MC; Rizzatti EG; Reinach FC
Braz J Infect Dis; 2021; 25(4):101604. PubMed ID: 34416142
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial.
Deckert A; Anders S; de Allegri M; Nguyen HT; Souares A; McMahon S; Boerner K; Meurer M; Herbst K; Sand M; Koeppel L; Siems T; Brugnara L; Brenner S; Burk R; Lou D; Kirrmaier D; Duan Y; Ovchinnikova S; Marx M; Kräusslich HG; Knop M; Bärnighausen T; Denkinger C
Trials; 2021 Jan; 22(1):39. PubMed ID: 33419461
[TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study.
Poustchi H; Darvishian M; Mohammadi Z; Shayanrad A; Delavari A; Bahadorimonfared A; Eslami S; Javanmard SH; Shakiba E; Somi MH; Emami A; Saki N; Hormati A; Ansari-Moghaddam A; Saeedi M; Ghasemi-Kebria F; Mohebbi I; Mansour-Ghanaei F; Karami M; Sharifi H; Pourfarzi F; Veisi N; Ghadimi R; Eghtesad S; Niavarani A; Ali Asgari A; Sadeghi A; Sorouri M; Anushiravani A; Amani M; Kaveh S; Feizesani A; Tabarsi P; Keyvani H; Markarian M; Shafighian F; Sima A; Sadjadi A; Radmard AR; Mokdad AH; Sharafkhah M; Malekzadeh R
Lancet Infect Dis; 2021 Apr; 21(4):473-481. PubMed ID: 33338441
[TBL] [Abstract][Full Text] [Related]
11. Antibody tests for identification of current and past infection with SARS-CoV-2.
Deeks JJ; Dinnes J; Takwoingi Y; Davenport C; Spijker R; Taylor-Phillips S; Adriano A; Beese S; Dretzke J; Ferrante di Ruffano L; Harris IM; Price MJ; Dittrich S; Emperador D; Hooft L; Leeflang MM; Van den Bruel A;
Cochrane Database Syst Rev; 2020 Jun; 6(6):CD013652. PubMed ID: 32584464
[TBL] [Abstract][Full Text] [Related]
12. Assessment of SARS-CoV-2 Seropositivity During the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults.
Tang X; Sharma A; Pasic M; Brown P; Colwill K; Gelband H; Birnboim HC; Nagelkerke N; Bogoch II; Bansal A; Newcombe L; Slater J; Rodriguez PS; Huang G; Fu SH; Meh C; Wu DC; Kaul R; Langlois MA; Morawski E; Hollander A; Eliopoulos D; Aloi B; Lam T; Abe KT; Rathod B; Fazel-Zarandi M; Wang J; Iskilova M; Pasculescu A; Caldwell L; Barrios-Rodiles M; Mohammed-Ali Z; Vas N; Santhanam DR; Cho ER; Qu K; Jha S; Jha V; Suraweera W; Malhotra V; Mastali K; Wen R; Sinha S; Reid A; Gingras AC; Chakraborty P; Slutsky AS; Jha P;
JAMA Netw Open; 2022 Feb; 5(2):e2146798. PubMed ID: 35171263
[TBL] [Abstract][Full Text] [Related]
13. Retrospective analysis of seroprevalence in a cohort of university students of Rome (Italy) between September 2020 and July 2021.
Ulivieri A; Morgante A; Magi F; Salehi LB; Lavra L
Epidemiol Prev; 2022; 46(5-6):367-375. PubMed ID: 36628641
[TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2 antibody seroprevalence in India, August-September, 2020: findings from the second nationwide household serosurvey.
Murhekar MV; Bhatnagar T; Selvaraju S; Saravanakumar V; Thangaraj JWV; Shah N; Kumar MS; Rade K; Sabarinathan R; Asthana S; Balachandar R; Bangar SD; Bansal AK; Bhat J; Chopra V; Das D; Deb AK; Devi KR; Dwivedi GR; Khan SMS; Kumar CPG; Kumar MS; Laxmaiah A; Madhukar M; Mahapatra A; Mohanty SS; Rangaraju C; Turuk A; Baradwaj DK; Chahal AS; Debnath F; Haq I; Kalliath A; Kanungo S; Kshatri JS; Lakshmi GGJN; Mitra A; Nirmala AR; Prasad GV; Qurieshi MA; Sahay S; Sangwan RK; Sekar K; Shukla VK; Singh PK; Singh P; Singh R; Varma DS; Viramgami A; Panda S; Reddy DCS; Bhargava B;
Lancet Glob Health; 2021 Mar; 9(3):e257-e266. PubMed ID: 33515512
[TBL] [Abstract][Full Text] [Related]
15. Disparities in SARS-CoV-2 Infection by Race, Ethnicity, Language, and Social Vulnerability: Evidence from a Citywide Seroprevalence Study in Massachusetts, USA.
Matias WR; Fulcher IR; Sauer SM; Nolan CP; Guillaume Y; Zhu J; Molano FJ; Uceta E; Collins S; Slater DM; Sánchez VM; Moheed S; Harris JB; Charles RC; Paxton RM; Gonsalves SF; Franke MF; Ivers LC
J Racial Ethn Health Disparities; 2024 Feb; 11(1):110-120. PubMed ID: 36652163
[TBL] [Abstract][Full Text] [Related]
16. Optimizing the implementation of a participant-collected, mail-based SARS-CoV-2 serological survey in university-affiliated populations: lessons learned and practical guidance.
Cramer EY; Snyder T; Ravenhurst J; Lover AA
BMC Public Health; 2022 Oct; 22(1):1907. PubMed ID: 36224583
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal Household Assessment of Respiratory Illness in Children and Parents During the COVID-19 Pandemic.
de Hoog MLA; Sluiter-Post JGC; Westerhof I; Fourie E; Heuvelman VD; Boom TT; Euser SM; Badoux P; Reusken C; Bont LJ; Sanders EAM; Jaddoe VWV; Herpers BL; Eggink D; Wildenbeest JG; Duijts L; van Houten MA; Bruijning-Verhagen PCJL
JAMA Netw Open; 2022 Oct; 5(10):e2237522. PubMed ID: 36264578
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and associated characteristics of anti-SARS-CoV-2 antibodies in Mexico 5 months after pandemic arrival.
Díaz-Salazar C; Sánchez-García A; Rodríguez-Gutiérrez R; Camacho-Ortiz A; Saldívar-Rodríguez D; González-González JG
BMC Infect Dis; 2021 Aug; 21(1):835. PubMed ID: 34412620
[TBL] [Abstract][Full Text] [Related]
19. Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19).
Kislaya I; Gonçalves P; Barreto M; Sousa R; Garcia AC; Matos R; Guiomar R; Rodrigues AP;
Acta Med Port; 2021 Feb; 34(2):87-94. PubMed ID: 33641702
[TBL] [Abstract][Full Text] [Related]
20. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in the staff of a public school system in the midwestern United States.
Lopez L; Nguyen T; Weber G; Kleimola K; Bereda M; Liu Y; Accorsi EK; Skates SJ; Santa Maria JP; Smith KR; Kalinich M
PLoS One; 2021; 16(6):e0243676. PubMed ID: 34111144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
